Overview

A Single-Dose Study of the Pharmacokinetics of Vibegron (MK-4618) in Adults With Hepatic Insufficiency (MK-4618-013)

Status:
Completed
Trial end date:
2013-06-14
Target enrollment:
Participant gender:
Summary
This study will investigate the pharmacokinetics of a single oral dose of vibegron (MK-4618) administered to participants with moderate hepatic insufficiency and healthy participants matched for age, gender, and body mass index (BMI). Participants may be enrolled with mild hepatic insufficiency.
Phase:
Phase 1
Details
Lead Sponsor:
Merck Sharp & Dohme Corp.